SORT OUT V: A new episode in the des wars

The Lancet

Volumn 381, Issue 9867, 2013, Pages 609-611

  Kastrati, Adnan ^a   Neumann, Franz Josef ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; RAPAMYCIN; UMIROLIMUS;

DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; NOTE; PRIORITY JOURNAL; STENT THROMBOSIS;

EID: 84874418347     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60055-0     Document Type: Note

References (15)

1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-80.
2. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369: 667-78.
3. Byrne RA, Iijima R, Mehilli J, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv 2009; 2: 291-99.
4. Koppara T, Joner M, Bayer G, Steigerwald K, Diener T, Wittchow E. Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation. Thromb Haemost 2012; 107: 1161-71.
5. de Waha A, Cassese S, Park DW, et al. Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. Clin Res Cardiol 2012; 101: 461-67.
6. Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012; 33: 1214-22.
7. Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011; 378: 1940-48.
8. Pendyala LK, Matsumoto D, Shinke T, et al. Nobori stent shows less vascular inflammation and early recovery of endothelial function compared with Cypher stent. JACC Cardiovasc Interv 2012; 5: 436-44.
9. Chevalier B, Serruys PW, Silber S, et al. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. EuroIntervention 2007; 2: 426-34.
10. Chevalier B, Silber S, Park SJ, et al. Randomized comparison of the Nobori biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial-phase 2. Circ Cardiovasc Interv 2009; 2: 188-95.
11. Kadota K, Muramatsu T, Iwabuchi M, et al. Randomized comparison of the Nobori biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries. Catheter Cardiovasc Interv 2012; 80: 789-96.
12. Danzi GB, Chevalier B, Urban P, et al. Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study. EuroIntervention 2012; 8: 109-16.
13. Christiansen EH, Jensen LO, Thayssen P, et al, for the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) V investigators. Biolimus-eluting biodegradable polymer-coated stent versus durable-polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet 2013; published online Jan 30. http://dx.doi. org/10.1016/S0140- 6736(12)61962-X.
14. Smits PC, Hofma S, Togni M, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet 2013; published online Jan 30. http://dx.doi.org/10.1016/S0140-6736(12)61852-2.
15. Galloe AM, Thuesen L, Kelbaek H, et al. Comparison of paclitaxel-and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA 2008; 299: 409-16.